1. BriaCell presents positive clinical data at the SABCS 2025. 2. Phase 3 study shows biomarkers may predict treatment responses. 3. Bria-IMT has strong safety profile with no toxicity-related discontinuations. 4. Patients with favorable NLR showed longer progression-free survival (PFS). 5. Phase 2 data supports promising clinical benefits for metastatic breast cancer.
FAQ
Why Bullish?
Positive clinical data can drive investor confidence, similar to successful FDA approvals in biotech. For instance, positive trial outcomes often result in stock surges.
How important is it?
The positive results and supportive data on biomarkers could lead to enhanced market perception and drive stock price higher.
Why Short Term?
Immediate investor reaction is likely after favorable clinical data presentation, as seen with past biotechnology stocks following positive study results.
BriaCell Showcases Promising Clinical Data at SABCS® 2025
On December 10, 2025, BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) revealed encouraging findings from its clinical studies at the San Antonio Breast Cancer Symposium (SABCS®) 2025. During the event, taking place from December 9-12 at the Henry B. Gonzalez Convention Center in San Antonio, Texas, the biotech company presented three clinical posters outlining data from their ongoing Phase 2 and Phase 3 studies of the Bria-IMT™ regimen combined with checkpoint inhibitors.
Key Findings from the Phase 3 Study
BriaCell's Phase 3 trial is designed to investigate the effectiveness of the Bria-IMT regimen in treating metastatic breast cancer. According to Dr. Kelly E. McCann, MD, PhD, at UCLA Health, the collected biomarker data could significantly enhance the ability to foresee clinical responses in patients undergoing treatment. This capability is especially crucial for those with limited treatment options due to the complex nature of metastatic breast cancer.
Supporting Evidence for Bria-IMT Regimen
Dr. Chaitali S. Nangia, MD, and a lead researcher on one of the posters stated, “BriaCell’s data shows the promise of the Bria-IMT regimen to address major unmet needs in the treatment of metastatic breast cancer.” This is particularly relevant for patients who have experienced progression after several lines of therapy, with a median of six prior treatments reported.
Poster Presentation Highlights
- Late-Breaking Abstract Number: 3688
- Presentation Title: Impact of Prior Therapy, Genotype Matching, and Biomarkers in the Bria-ABC Phase 3 Trial
- Presentation Date/Time: December 10, 2025, 12:30 PM - 2:00 PM CST
Study Summary and Key Findings
The pivotal Phase 3 study randomized patients into three groups: one receiving the Bria-IMT plus an immune checkpoint inhibitor (CPI), one receiving Bria-IMT monotherapy, and the last receiving a Treatment of Physician’s Choice (TPC). An interim analysis of 116 patients revealed no treatment-related discontinuations due to adverse effects (AEs), with common AEs including fatigue, anemia, and low-grade nausea.
Potential Predictive Biomarkers
The Neutrophil-to-Lymphocyte Ratio (NLR) surfaced as a potential predictive biomarker, indicating significant correlation with progression-free survival (PFS). Patients with a favorable NLR of 0.7 to 2.3 showed a median PFS of 4.4 months, compared to 2.6 months for those outside this range.
Additional Findings from Phase 2 Studies
- Abstract Number: 3713
- Presentation Title: Survival Results of Phase II Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine
- Presentation Date/Time: December 10, 2025, 12:30 PM - 2:00 PM CST
The analysis demonstrated that positive Delayed Type Hypersensitivity (DTH) significantly increased median overall survival (OS) to 11.3 months compared to just 4.7 months for DTH-negative patients. The best clinical benefit rates for patients with central nervous system (CNS) metastasis in HER2+ and HR+ categories were 100% and 75%, respectively.
Future Directions and Conclusion
BriaCell’s results emphasize the potential of the Bria-IMT regimen in fulfilling critical therapeutic gaps in metastatic breast cancer treatment, particularly for patients with few remaining options. As the Phase 3 study continues, establishing biomarker-driven, personalized treatment strategies remains a focus for the company's clinical advancement. Detailed presentations of these results are available at BriaCell's website.
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology firm dedicated to developing innovative immunotherapies aimed at transforming cancer care.